Literature DB >> 23518498

A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors.

Valerie Edmond1, Galina Merdzhanova, Stephanie Gout, Elisabeth Brambilla, Sylvie Gazzeri, Beatrice Eymin.   

Abstract

The transcription factor E2F1 belongs to the E2F family and plays a crucial role during cell cycle progression and apoptosis. Ser/Arg-Rich (SR) proteins are a family of RNA-binding phosphoproteins that control both constitutive and alternative pre-mRNA splicing events. We previously identified the SR protein SRSF2 as a new transcriptional target of E2F1 and demonstrated that both proteins cooperate to induce apoptosis in non-small cell lung carcinoma. In this study, we postulated that SRSF2 is also involved in the proliferative functions of E2F1. Using IHC, we first demonstrate that SRSF2 and its phosphorylated form (P-SRSF2) are overexpressed in neuroendocrine lung tumors that are highly proliferative tumors expressing high levels of E2F1. Importantly, we show a direct correlation between cyclin E, an E2F1-target gene controlling S phase, and P-SRSF2 proteins levels (p = 0.0083), suggesting a role of SRSF2 in E2F1-mediated cellular proliferation. Accordingly, using neuroendocrine lung carcinoma cell lines, we demonstrate that SRSF2 is a cell cycle-regulated protein involved in entry and progression into S phase. We also provide evidence that SRSF2 interacts with E2F1 and stimulates its transcriptional control of cell cycle target genes such as cyclin E. Finally, we show that inhibition of AKT signaling pathway prevents SRSF2 phosphorylation and activity toward E2F1 transcriptional function. Taken together, these results identify a new role of SRSF2 in the control of cell cycle progression and reinforce the functional link between SRSF2 and E2F1 proteins.

Entities:  

Keywords:  AKT; E2F1; SRSF2; cellular proliferation; neuroendocrine lung tumors; p45SKP2

Mesh:

Substances:

Year:  2013        PMID: 23518498      PMCID: PMC3674091          DOI: 10.4161/cc.24363

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  30 in total

1.  SC35 plays a role in T cell development and alternative splicing of CD45.

Authors:  H Y Wang; X Xu; J H Ding; J R Bermingham; X D Fu
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma.

Authors:  B Eymin; S Gazzeri; C Brambilla; E Brambilla
Journal:  Oncogene       Date:  2001-03-29       Impact factor: 9.867

Review 3.  The Rb/E2F pathway: expanding roles and emerging paradigms.

Authors:  J W Harbour; D C Dean
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

4.  U1 snRNA associates with TFIIH and regulates transcriptional initiation.

Authors:  Kon Yew Kwek; Shona Murphy; Andre Furger; Benjamin Thomas; William O'Gorman; Hiroshi Kimura; Nick J Proudfoot; Alexandre Akoulitchev
Journal:  Nat Struct Biol       Date:  2002-11

5.  Promoter proximal splice sites enhance transcription.

Authors:  Andre Furger; Justin M O'Sullivan; Alexandra Binnie; Barbara A Lee; Nick J Proudfoot
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

Review 6.  Hitting their targets: an emerging picture of E2F and cell cycle control.

Authors:  Alexandre Blais; Brian David Dynlacht
Journal:  Curr Opin Genet Dev       Date:  2004-10       Impact factor: 5.578

7.  Coordinate regulation of transcription and splicing by steroid receptor coregulators.

Authors:  Didier Auboeuf; Arnd Hönig; Susan M Berget; Bert W O'Malley
Journal:  Science       Date:  2002-10-11       Impact factor: 47.728

8.  Blastocyst formation is blocked in mouse embryos lacking the splicing factor SRp20.

Authors:  H Jumaa; G Wei; P J Nielsen
Journal:  Curr Biol       Date:  1999-08-26       Impact factor: 10.834

9.  Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart.

Authors:  Jian-Hua Ding; Xiangdong Xu; Dongmei Yang; Pao-Hsien Chu; Nancy D Dalton; Zhen Ye; Joanne M Yeakley; Heping Cheng; Rui-Ping Xiao; John Ross; Ju Chen; Xiang-Dong Fu
Journal:  EMBO J       Date:  2004-02-12       Impact factor: 11.598

10.  Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes.

Authors:  Didier Auboeuf; Dennis H Dowhan; Yun Kyoung Kang; Kimberly Larkin; Jae Woon Lee; Susan M Berget; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  11 in total

Review 1.  The RNAissance family: SR proteins as multifaceted regulators of gene expression.

Authors:  Jonathan M Howard; Jeremy R Sanford
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-08-22       Impact factor: 9.957

Review 2.  The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression.

Authors:  Asaf Shilo; Zahava Siegfried; Rotem Karni
Journal:  Mol Cell Oncol       Date:  2014-12-01

3.  Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Authors:  S T Workenhe; T Ketela; J Moffat; B P Cuddington; K L Mossman
Journal:  Oncogene       Date:  2015-08-10       Impact factor: 9.867

Review 4.  Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Authors:  Sergio Pedraza-Arévalo; Manuel D Gahete; Emilia Alors-Pérez; Raúl M Luque; Justo P Castaño
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 5.  Splicing factor SRSF2-centric gene regulation.

Authors:  Kun Li; Ziqiang Wang
Journal:  Int J Biol Sci       Date:  2021-04-16       Impact factor: 6.580

Review 6.  Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment.

Authors:  Anthony J Murphy; Alex H Li; Peichao Li; Hong Sun
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

7.  USP15 regulates dynamic protein-protein interactions of the spliceosome through deubiquitination of PRP31.

Authors:  Tanuza Das; Joon Kyu Park; Jinyoung Park; Eunji Kim; Michael Rape; Eunice EunKyeong Kim; Eun Joo Song
Journal:  Nucleic Acids Res       Date:  2017-05-05       Impact factor: 16.971

8.  Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.

Authors:  Li Yang; Yixuan Hou; Jie Yuan; Shifu Tang; Hailong Zhang; Qing Zhu; Yan-e Du; Mingli Zhou; Siyang Wen; Liyun Xu; Xi Tang; Xiaojiang Cui; Manran Liu
Journal:  Oncotarget       Date:  2015-09-22

9.  Decreased Expression of SRSF2 Splicing Factor Inhibits Apoptotic Pathways in Renal Cancer.

Authors:  Hanna Kędzierska; Piotr Popławski; Grażyna Hoser; Beata Rybicka; Katarzyna Rodzik; Elżbieta Sokół; Joanna Bogusławska; Zbigniew Tański; Anna Fogtman; Marta Koblowska; Agnieszka Piekiełko-Witkowska
Journal:  Int J Mol Sci       Date:  2016-09-28       Impact factor: 5.923

10.  Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer.

Authors:  Xin Li; Shaoyu Yang; Minna Zhang; Shuhuan Xie; Zefeng Xie
Journal:  Eur J Histochem       Date:  2019-12-11       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.